Medical devices leads Johnson & Johnson 2005 sales

Worldwide sales for the year 2005 were $50.5 billion, an increase of 6.7% over 2004. The Medical Devices and Diagnostics segment achieved overall annual sales of $19.1 billion in 2005, representing an increase over 2004 of 13.1% with operational growth of 12.5%. US sales increased 10.6%, while international sales increased 15.7%.

Cordis' circulatory disease management products were a key contributor to the segment results with the primary driver being the CYPHER Sirolimus-eluting Coronary Stent, which reduces restenosis (reblockage) of a treated coronary artery. The company says that CYPHER is the worldwide leader in drug-eluting stents with more than 1.7 million patients.

Also contributing to the strong performance of the segment were the results from DePuy's orthopaedic joint reconstruction and spinal products, LifeScan's blood glucose monitoring products, Vistakon's disposable contact lenses and Ortho-Clinical Diagnostics' professional diagnostic products.

During the fourth quarter, the Company announced that it had entered into a definitive agreement to acquire Animas Corporation, a leading manufacturer of insulin infusion pumps and related products. In January 2006, the Company also announced the acquisition of Hand Innovations LLC, a privately held manufacturer of implants used for the repair of wrist fractures.

Worldwide Pharmaceutical sales of $22.3 billion for the full year 2005 represented an increase of .9% versus the prior year with operational growth of .4% and a positive impact from currency of .5%. Domestic sales decreased 3.2%, while international sales increased 9.4% (7.8% from operations and 1.6% from currency).

"The year 2005 was a solid one for Johnson & Johnson, despite significant challenges," said William C. Weldon, Chairman and Chief Executive Officer. "We delivered excellent full-year earnings results, while continuing to make the major investments that will fuel future growth."

Full financial statement:

To top

To top